These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 30257705)

  • 1. CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway.
    Graule J; Uth K; Fischer E; Centeno I; Galván JA; Eichmann M; Rau TT; Langer R; Dawson H; Nitsche U; Traeger P; Berger MD; Schnüriger B; Hädrich M; Studer P; Inderbitzin D; Lugli A; Tschan MP; Zlobec I
    Clin Epigenetics; 2018 Sep; 10(1):120. PubMed ID: 30257705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
    Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
    Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
    Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation of CDX2 as a Predictor in Poor Clinical Outcome of Patients with Colorectal Cancer.
    Jiang G; Luo C; Sun M; Zhao Z; Li W; Chen K; Fan T
    Genet Test Mol Biomarkers; 2016 Nov; 20(11):710-714. PubMed ID: 27754705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.
    Lundberg IV; Edin S; Eklöf V; Öberg Å; Palmqvist R; Wikberg ML
    BMC Cancer; 2016 Jul; 16():471. PubMed ID: 27411517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different involvement of DNA methylation and histone deacetylation in the expression of solute-carrier transporters in 4 colon cancer cell lines.
    Ikehata M; Ueda K; Iwakawa S
    Biol Pharm Bull; 2012; 35(3):301-7. PubMed ID: 22382314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JARID1B promotes colorectal cancer proliferation and Wnt/β-catenin signaling via decreasing CDX2 level.
    Huang D; Xiao F; Hao H; Hua F; Luo Z; Huang Z; Li Q; Chen S; Cheng X; Zhang X; Fang W; Hu X; Liu F
    Cell Commun Signal; 2020 Oct; 18(1):169. PubMed ID: 33109187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter methylation inhibits APC gene expression by causing changes in chromatin conformation and interfering with the binding of transcription factor CCAAT-binding factor.
    Deng G; Song GA; Pong E; Sleisenger M; Kim YS
    Cancer Res; 2004 Apr; 64(8):2692-8. PubMed ID: 15087381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium-sensing receptor silencing in colorectal cancer is associated with promoter hypermethylation and loss of acetylation on histone 3.
    Fetahu IS; Höbaus J; Aggarwal A; Hummel DM; Tennakoon S; Mesteri I; Baumgartner-Parzer S; Kállay E
    Int J Cancer; 2014 Nov; 135(9):2014-23. PubMed ID: 24691920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing of CDX2 expression in colon cancer via a dominant repression pathway.
    Hinoi T; Loda M; Fearon ER
    J Biol Chem; 2003 Nov; 278(45):44608-16. PubMed ID: 12947088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription.
    Zhang Y; Fatima N; Dufau ML
    Mol Cell Biol; 2005 Sep; 25(18):7929-39. PubMed ID: 16135786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
    Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
    Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.
    Baba Y; Nosho K; Shima K; Freed E; Irahara N; Philips J; Meyerhardt JA; Hornick JL; Shivdasani RA; Fuchs CS; Ogino S
    Clin Cancer Res; 2009 Jul; 15(14):4665-73. PubMed ID: 19584150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression.
    Claus R; Fliegauf M; Stock M; Duque JA; Kolanczyk M; Lübbert M
    J Leukoc Biol; 2006 Dec; 80(6):1462-72. PubMed ID: 17000900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
    Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
    Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer.
    Yamada N; Hamada T; Goto M; Tsutsumida H; Higashi M; Nomoto M; Yonezawa S
    Int J Cancer; 2006 Oct; 119(8):1850-7. PubMed ID: 16721789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma.
    Slik K; Turkki R; Carpén O; Kurki S; Korkeila E; Sundström J; Pellinen T
    Am J Surg Pathol; 2019 Nov; 43(11):1473-1482. PubMed ID: 31490234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation and expression of the tumour suppressor, PRDM5, in colorectal cancer and polyp subgroups.
    Bond CE; Bettington ML; Pearson SA; McKeone DM; Leggett BA; Whitehall VL
    BMC Cancer; 2015 Jan; 15():20. PubMed ID: 25613750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island.
    Zhao W; Soejima H; Higashimoto K; Nakagawachi T; Urano T; Kudo S; Matsukura S; Matsuo S; Joh K; Mukai T
    J Biochem; 2005 Mar; 137(3):431-40. PubMed ID: 15809347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.